Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +9

Lysis of tumor cells by natural killer cells in mice is impeded by platelets.

Bernhard Nieswandt, Michael Häfner, Bernd Echtenacher et al. · PubMed · 1999 · 838 citations

Life Sciences, Immunology, Oncology +13

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

George D. Demetri, Margaret von Mehren, Robin L. Jones et al. · Journal of Clinical Oncology · 2015 · 834 citations · Full text

Medicine, Oncology, Pharmacology +17

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 766 citations · Full text

Medicine, Oncology, Pharmacology +12

Antimetastatic effects associated with platelet reduction.

G Gasic, Tatiana B. Gasic, Carleton C. Stewart · Proceedings of the National Academy of Sciences · 1968 · 739 citations · Full text

Medicine, Cancer Biology, Oncology +9